Thoratec has enrolled the first patient in a study intended to evaluate and compare the effectiveness of the HeartMate II left ventricular assist system as a destination therapy device in heart failure patients.
The prospective, multi-centre, non-randomised, controlled and observational ROADMAP post-market study will enrol 200 patients in one of two cohorts – optimal medical management or left ventricular assist device.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The primary endpoint will be survival and functional improvement, as measured by the six-minute walk test at one year, while secondary endpoints include actuarial survival, quality of life, pump replacement, adverse events and rehospitalisation.
HeartMate II is a continuous-flow left ventricular assist device, designed to provide long-term cardiac support. It can pump up to 10l of blood per minute.
